Longitudinal Changes in Utility Scores and Health-Related Quality of Life During Interferon-Free Direct-Acting Antiviral Therapy for Chronic Hepatitis C in Japan: Implications for Cost–Utility Analysis
Livers · 12.08.2026 · 6 (4) · 78
DOI: 10.3390/livers6040078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Livers, online erschienen am 12.08.2026. Verfasst von Maki Hirao und 14 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Labour Sciences Research Grants for Research on Hepatitis.
Abstract (Originalsprache)
Background/Objectives: Interferon-free direct-acting antiviral (DAA) therapy cures chronic hepatitis C virus (HCV) infection, but its short-term effects on health-related quality of life (HRQoL) are captured differently by generic and disease-specific instruments. We examined longitudinal changes in utility scores and HRQoL in a multicenter Japanese cohort.
Methods
Adults with chronic HCV completed the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L), the 8-Item Short-Form Health Survey (SF-8), and the Chronic Liver Disease Questionnaire (CLDQ) at baseline and at 12, 24, and 36 weeks after treatment initiation; 48-week data were included when available. Complete-case panels were analyzed for each instrument (SF-8, n = 112; CLDQ, n = 131; EQ-5D-5L, n = 128). Domain trajectories were summarized and compared with baseline.
Results
By week 36, SF-8 general health improved significantly from 50.42 to 52.47, whereas vitality (50.73 to 52.55) and mental health (51.02 to 53.05) showed nonsignificant numerical increases. CLDQ showed improvements in worry (5.21 to 5.82) and total score (5.21 to 5.47). EQ-5D-5L utility values remained high and largely stable (0.913 to 0.920), suggesting ceiling effects in patients with relatively good baseline health status. External real-world evidence also suggested better on-treatment HRQoL with ribavirin-free regimens.
Conclusions
In Japanese patients with HCV, interferon-free DAA therapy was associated with early improvements in symptom-proximal and mental domains of HRQoL. Generic utility scores changed little over the short term, indicating that disease-specific patient-reported outcome (PRO) instruments and utility measures should be used together for patient-centered assessment and cost–utility modeling.
Förderung
- Health and Labour Sciences Research Grants for Research on Hepatitis
Zitieren
APA
Hirao, M., Sugimori, H., Igarashi, A., Yatsuhashi, H., Satoh, T., Ikeda, S., Masaki, N., Yotsuyanagi, H., Takura, T., Yoda, T., Akazawa, M., Suka, M., Ito, N., Odajima, T., & Hirao, T. (2026). Longitudinal Changes in Utility Scores and Health-Related Quality of Life During Interferon-Free Direct-Acting Antiviral Therapy for Chronic Hepatitis C in Japan: Implications for Cost–Utility Analysis. Livers, 6(4), 78. https://doi.org/10.3390/livers6040078
Vancouver
Hirao M, Sugimori H, Igarashi A, Yatsuhashi H, Satoh T, Ikeda S, et al. Longitudinal Changes in Utility Scores and Health-Related Quality of Life During Interferon-Free Direct-Acting Antiviral Therapy for Chronic Hepatitis C in Japan: Implications for Cost–Utility Analysis. Livers. 2026;6(4):78. doi:10.3390/livers6040078
BibTeX
@article{Hirao2026,
author = {Hirao, Maki and Sugimori, Hiroki and Igarashi, Ataru and Yatsuhashi, Hiroshi and Satoh, Toshihiko and Ikeda, Shunya and Masaki, Naohiko and Yotsuyanagi, Hiroshi and Takura, Tomoyuki and Yoda, Takeshi and Akazawa, Manabu and Suka, Machi and Ito, Naoko and Odajima, Takeshi and Hirao, Tomohiro},
title = {Longitudinal Changes in Utility Scores and Health-Related Quality of Life During Interferon-Free Direct-Acting Antiviral Therapy for Chronic Hepatitis C in Japan: Implications for Cost–Utility Analysis},
journal = {Livers},
year = {2026},
volume = {6},
number = {4},
pages = {78},
doi = {10.3390/livers6040078}
}
EUVIMED